Study to Compare the Efficacy and Safety of F-627 and GRAN®

NCT04174599 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

242

Enrollment

INDUSTRY

Sponsor class

Conditions

Breast Cancer
Neutropenia

Interventions

DRUG: F-627
DRUG: GRAN®

Sponsor

EVIVE Biotechnology